AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with E

11-06-2014 Business Wire HealthComments (0)

BiotechnologyBristol-Myers SquibbOrenciaPharmaceutical

Bristol-Myers Squibb Company (NYSE:BMY) announced today its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia (abatacept), in combination with methotrexate (MTX) achieved significantly higher rates of DAS-defined (DAS28 CRP <2.6) remission at 12 months than treatment with standard of care agent MTX (60.9% vs. 45.2%, respectively), in biologic and MTX-naïve patients with early active RA. The data

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top